文献速递功能神经外科

长期抗血小板或抗凝治疗患者的脑深部电刺激手术安全性

Deep brain stimulation in patients on chronic antiplatelet or anticoagulation treatment.
PubMed 文献 · Acta Neurochir (Wien) · 2021-08-03

本研究纳入465例功能性立体定向神经外科手术患者,其中34例在脑深部电刺激(DBS)术前术后接受长期抗血小板或抗凝治疗,围术期抗血小板药停用、维生素K拮抗剂或新型口服抗凝药(NOACs)以肝素桥接。结果显示长期治疗组颅内出血2/34(5.9%),未治疗组15/431(3.5%),差异无统计学意义;随访1年无出血并发症,提示DBS手术在此类患者中可行。

要点

  • 长期抗血小板或抗凝患者DBS围术期颅内出血率5.9%,与未治疗者3.5%无显著差异
  • 抗血小板药围术期停用,维生素K拮抗剂或NOACs以肝素桥接
  • 随访1年无出血并发症,但需严格患者选择与标准化围术期管理

核心结论

  • 长期抗血小板或抗凝治疗的DBS手术患者颅内出血风险未显著增加
  • DBS手术在此类患者中可行,术后1年随访无出血并发症

研究设计与样本

  • 回顾性分析465例功能性立体定向神经外科手术患者,其中34例接受长期抗血小板或抗凝治疗
  • 抗血小板药围术期停用,维生素K拮抗剂或NOACs以肝素桥接
  • 全部患者术后行立体定向CT扫描并随访1年

主要发现

  • 长期治疗组颅内出血2/34(5.9%),未治疗组15/431(3.5%),差异无统计学意义
  • 长期治疗组脉冲发生器囊袋血肿2/34(5.9%),未治疗组4/426(0.9%)
  • 血栓栓塞并发症仅2例,均发生于未接受长期治疗的患者

临床怎么用

  • 对合并心血管共病需长期抗血小板或抗凝的DBS候选患者,不应仅因此视为禁忌
  • 围术期按方案停用抗血小板药、对维生素K拮抗剂或NOACs行肝素桥接,并重视患者选择与标准化管理

局限性

  • 长期治疗组样本量小(34例),事件数少
  • 为单中心回顾性设计,组间比较需谨慎解读

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the aging society, many patients with movement disorders, pain syndromes, or psychiatric disorders who are candidates for deep brain stimulation (DBS) surgery suffer also from cardiovascular co-morbidities that require chronic antiplatelet or anticoagulation treatment. Because of a presumed increased risk of intracranial hemorrhage during or after surgery and limited knowledge about perioperative management, chronic antiplatelet or anticoagulation treatment often has been considered a relative contraindication for DBS. Here, we evaluate whether or not there is an increased risk for intracranial hemorrhage or thromboembolic complications in patients on chronic treatment (paused for surgery or bridged with subcutaneous heparin) as compared to those without. METHODS: Out of a series of 465 patients undergoing functional stereotactic neurosurgery, 34 patients were identified who were on chronic treatment before and after receiving DBS. In patients with antiplatelet treatment, medication was stopped in the perioperative period. In patients with vitamin K antagonists or novel oral anticoagulants (NOACs), heparin was used for bridging. All patients had postoperative stereotactic CT scans, and were followed up for 1 year after surgery. RESULTS: In patients on chronic antiplatelet or anticoagulation treatment, intracranial hemorrhage occurred in 2/34 (5.9%) DBS surgeries, whereas the rate of intracranial hemorrhage was 15/431 (3.5%) in those without, which was statistically not significant. Implantable pulse generator pocket hematomas were seen in 2/34 (5.9%) surgeries in patients on chronic treatment and in 4/426 (0.9%) without. There were only 2 instances of thromboembolic complications which both occurred in patients without chronic treatment. There were no hemorrhagic complications during follow-up for 1 year. CONCLUSIONS: DBS surgery in patients on chronic antiplatelet or anticoagulation treatment is feasible. Also, there was no increased risk of hemorrhage in the first year of follow-up after DBS surgery. Appropriate patient selection and standardized perioperative management are necessary to reduce the risk of intracranial hemorrhage and thromboembolic complications.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Runge J, Cassini Ascencao L, Blahak C, et al. Deep brain stimulation in patients on chronic antiplatelet or anticoagulation treatment. Acta Neurochir (Wien). 2021. PMID: 34342730. doi:10.1007/s00701-021-04931-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。